Review Article
Tuberculous Meningitis: Diagnosis and Treatment Overview
Table 2
Pharmacokinetic activity and CSF penetration of anti-TB drugs.
| | Anti-TB drug | Activity | CSF penetration |
| 1st-line drugs | Isoniazid | Cidal | 90%–95% | Rifampin | Cidal | 5%–25% | Pyrazinamide | Cidal | 95%–100% | Streptomycin | Static | 20%–25% | Ethambutol | Static | 10%–50% | Ciprofloxacin | Cidal | 15%–35% | Levofloxacin | Cidal | 60%–80% | Moxifloxacin | Cidal | 70%–80% |
| 2nd-line drugs | Ethionamide | Cidal | 80%–95% | Cycloserine | Static | 40%–70% | Amikacin | Cidal | 10%–25% | Streptomycin | Cidal | 10%–20% | Capreomycin | Static | unknown | Para-aminosalicylic acid | Static | unknown | Thioacetazone | Static | unknown | Linezolid | Cidal | 80%–100% |
| New agents | Bedaquiline (TMC207) | Cidal | unknown | Delamanid (OPC-67683) | Cidal | unknown |
|
|
Cidal: bactericidal, Static: bacteriostatic.
|